Related Experiment Video

Updated: Oct 29, 2025

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction
10:35

A Blood-based Test for the Detection of ROS1 and RET Fusion Transcripts from Circulating Ribonucleic Acid Using Digital Polymerase Chain Reaction

Published on: April 5, 2018

10.5K

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report

Guangdie Yang1, Jie Wang1, Yinan Yao1

  • 1Department of Respiratory Medicine, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Frontiers in Oncology
|July 8, 2021
PubMed

Insights

ROS1 rearrangements are rare in lung squamous cell carcinoma but can respond to crizotinib. This case highlights the importance of testing for ROS1 alterations in lung squamous cell carcinoma for targeted therapy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • ROS1 rearrangements are established driver mutations in lung adenocarcinoma, occurring in 1-2% of cases.
  • These rearrangements are exceptionally rare in lung squamous cell carcinoma.
  • Peripheral lung cancer presentation is common in lung squamous cell carcinoma.

Observation:

  • This study reports a rare case of lung squamous cell carcinoma with a ROS1 rearrangement.
  • The patient presented with a peripheral lung cancer radiological manifestation.
  • The tumor exhibited high sensitivity to crizotinib treatment.

Findings:

  • The presence of ROS1 rearrangement in lung squamous cell carcinoma is confirmed.
  • The tumor responded favorably to crizotinib, a targeted therapy drug.
  • This indicates that ROS1 rearrangements can be actionable in lung squamous cell carcinoma.

Implications:

  • Clinicians should consider ROS1 rearrangement testing in lung squamous cell carcinoma patients.
  • Crizotinib may be a viable treatment option for a subset of lung squamous cell carcinoma patients with ROS1 alterations.
  • This finding expands the scope of targeted therapy in non-small cell lung cancer subtypes.
Keywords:
ROS1 rearrangementatypical imaging manifestationcrizotinibhypoalbuminemialung squamous carcinoma

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.3K

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K